|
1
|
Stupp R, Hegi ME, Mason WP, van den Bent
MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B,
Belanger K, et al: Effects of radiotherapy with concomitant and
adjuvant temozolomide versus radiotherapy alone on survival in
glioblastoma in a randomised phase III study: 5-year analysis of
the EORTC-NCIC trial. Lancet Oncol. 10:459–466. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sanai N, Chang S and Berger MS: Low-grade
gliomas in adults. J Neurosurg. 115:948–965. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Stewart LA: Chemotherapy in adult
high-grade glioma: A systematic review and meta-analysis of
individual patient data from 12 randomised trials. Lancet.
359:1011–1018. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Athanassiou H, Synodinou M, Maragoudakis
E, Paraskevaidis M, Verigos C, Misailidou D, Antonadou D, Saris G,
Beroukas K and Karageorgis P: Randomised phase II study of
temozolomide and radiotherapy compared with radiotherapy alone in
newly diagnosed glioblastoma multiforme. J Clin Oncol.
23:2372–2377. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mason WP, Maestro RD, Eisenstat D, Forsyth
P, Fulton D, Laperrière N, Macdonald D, Perry J and Thiessen B:
Canadian GBM Recommendations Committee: Canadian recommendations
for the treatment of glioblastoma multiforme. Curr Oncol.
14:110–117. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Masuda TA, Inoue H, Sonoda H, Mine S,
Yoshikawa Y, Nakayama K, Nakayama K and Mori M: Clinical and
biological significance of S-phase kinase-associated protein 2
(Skp2) gene expression in gastric carcinoma: Modulation of
malignant phenotype by Skp2 overexpression, possibly via p27
proteolysis. Cancer Res. 62:3819–3825. 2002.PubMed/NCBI
|
|
7
|
Rosenblum MK: The 2007 WHO Classification
of Nervous System Tumors: Newly recognized members of the mixed
glioneuronal group. Brain Pathol. 17:308–313. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Weller M: Management of gliomas: Relevance
of molecular markers for clinical practice. Eur Assoc Neuro Oncol
Magazine. 2:6–10. 2012.
|
|
9
|
Shaw E, Arusell R, Scheithauer B, et al:
Prospective randomized trial of low-versus high-dose radiation
therapy in adults with supratentorial low-grade glioma: Initial
report of a North Central Cancer Treatment Group/Radiation Therapy
Oncology Group/Eastern Cooperative Oncology Group study. J Clin
Oncol. 20:2267–2276. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al: Radiotherapy plus concomitant and adjuvant temozolomide
for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Takanami I: The prognostic value of
overexpression of Skp2 mRNA in non-small cell lung cancer. Oncol
Rep. 13:727–731. 2005.PubMed/NCBI
|
|
12
|
Kamata Y, Watanabe J, Nishimura Y, Arai T,
Kawaguchi M, Hattori M, Obokata A and Kuramoto H: High expression
of skp2 correlates with poor prognosis in endometrial endometrioid
adenocarcinoma. J Cancer Res Clin Oncol. 131:591–596. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Pedeutour-Braccini Z, Burel-Vandenbos F,
Gozé C, Roger C, Bazin A, Costes-Martineau V, Duffau H and Rigau V:
Microfoci of malignant progression in diffuse low-grade gliomas:
Towards the creation of an intermediate grade in glioma
classification? Virchows Arch. 466:433–444. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Westhoff MA, Zhou S, Nonnenmacher L,
Karpel-Massler G, Jennewein C, Schneider M, Halatsch ME, Carragher
NO, Baumann B, Krause A, et al: Inhibition of NF-κ B signaling
ablates the invasive phenotype of glioblastoma. Mol Cancer Res.
11:1611–1623. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yang G, Ayala G, De Marzo A, Tian W,
Frolov A, Wheeler TM, Thompson TC and Harper JW: Elevated Skp2
protein expression in human prostate cancer: Association with loss
of the cyclin-dependent kinase inhibitor p27 and PTEN and with
reduced recurrence-free survival. Clin Cancer Res. 8:3419–3426.
2002.PubMed/NCBI
|
|
16
|
Ezoe S, Matsumura I, Nakata S, Gale K,
Ishihara K, Minegishi N, Machii T, Kitamura T, Yamamoto M, Enver T,
et al: GATA-2/estrogen receptor chimera regulates
cytokine-dependent growth of hematopoietic cells through
accumulation of p21 (WAF1) and p27 (Kip1) proteins. Blood.
100:3512–3520. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kudo Y, Kitajima S, Sato S, Miyauchi M,
Ogawa I and Takata T: High expression of S-phase kinase-interacting
protein 2, human F-box protein, correlates with poor prognosis in
oral squamous cell carcinomas. Cancer Res. 61:7044–7047.
2001.PubMed/NCBI
|
|
18
|
Van Meir EG, Hadjipanayis CG, Norden AD,
Shu HK, Wen PY and Olson J: Exciting new advances in
neuro-oncology: The avenue to a cure for malignant glioma. CA
Cancer J Clin. 60:166–193. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mamillapalli R, Gavrilova N, Mihaylova VT,
Tsvetkov LM, Wu H, Zhang H and Sun H: PTEN regulates the
ubiquitin-dependent degradation of the CDK inhibitor p27 (KIP1)
through the ubiquitin E3 ligase SCF (SKP2). Curr Biol. 11:263–267.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Dong Y, Sui L, Watanabe Y, Sugimoto K and
Tokuda M: S-phase kinase-associated protein 2 expression in
laryngeal squamous cell carcinomas and its prognostic implications.
Oncol Rep. 10:321–325. 2003.PubMed/NCBI
|
|
21
|
Koumarianou A, Tzeveleki I, Mekras D,
Eleftheraki AG, Bobos M, Wirtz R, Fountzilas E, Valavanis C,
Xanthakis I, Kalogeras KT, et al: Prognostic markers in early-stage
colorectal cancer: Significance of TYMS mRNA expression. Anticancer
Res. 34:4949–4962. 2014.PubMed/NCBI
|
|
22
|
Gotanda K, Hirota T, Matsumoto N and Ieiri
I: MicroRNA-433 negatively regulates the expression of thymidylate
synthase (TYMS) responsible for 5-fluorouracil sensitivity in HeLa
cells. BMC Cancer. 13:3692013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
von der Lehr N, Johansson S, Wu S, Bahram
F, Castell A, Cetinkaya C, Hydbring P, Weidung I, Nakayama K,
Nakayama KI, et al: The F-box protein Skp2 participates in c-Myc
proteosomal degradation and acts as a cofactor for c-Myc-regulated
transcription. Mol Cell. 11:1189–1200. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Latres E, Chiarle R, Schulman BA,
Pavletich NP, Pellicer A, Inghirami G and Pagano M: Role of the
F-box protein Skp2 in lymphomagenesis. Proc Natl Acad Sci USA.
98:2515–2520. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Qin L, Wang CZ, Fan HJ, Zhang CJ, Zhang
HW, Lv MH and Cui SD: A dual-targeting liposome conjugated with
transferrin and arginine-glycine-aspartic acid peptide for
glioma-targeting therapy. Oncol Lett. 8:2000–2006. 2014.PubMed/NCBI
|
|
26
|
Hua W, Yao Y, Chu YW, Zhong P, Zhang R,
Zhu W, Wu JS, Ma DX, Xu M, Mao Y and Zhou LF: Phase I study of
dendritic cells pulsed with tumor stem-like cells associated
antigens against malignant glioma in recurrent patients. Chin J
Neurosurg. 27:90–93. 2011.
|
|
27
|
Hart MG, Grant R, Garside R, Rogers G,
Somerville M and Stein K: Temozolomide for high grade glioma.
Cochrane Database Syst Rev. 8:CD0074152008.
|
